- TRAIL-induced apoptosis of HL60 leukemia cells: two distinct phenotypes of acquired TRAIL resistance that are accompanied with resistance to TNF alpha but not to idarubicin and cytarabine2009 | First Faculty of Medicine
- Idarubicin-induced apoptosis in HL-60 cells: Relationship between apoptosis and time dependence of apoptosis on idarubicin dosePublication without faculty affiliation
- TRAIL potencuje cytotoxické účinky idarubicinu a cytosin arabinosidu na leukemické buňkyPublication without faculty affiliation
- Dose dependent biological effects of Idarubicin in HL-60 cells: Alterations of the cell-cycle and apoptosis2000 | Faculty of Medicine in Hradec Králové
- Randomized trial comparing liposomal daunorubicin with idarubicin as induction for pediatric acute myeloid leukemia: results from Study AML-BFM 20042013 | Second Faculty of Medicine
- Monitoring of cardiotoxicity during induction chemotherapy containing idarubicin in acute myeloid leukemia with circulating markersPublication without faculty affiliation
- Anthracyclines and their metabolism in human liver microsomes and the participation of the new microsomal carbonyl reductase2011 | Faculty of Pharmacy in Hradec Králové
- Intermediate Dose Cytarabine/Idarubicin Induction and Non-Ara-C Containing Intensification in Newly Diagnosed De novo Adult Acute Myeloid Leukemia Under 60 YearsPublication without faculty affiliation
- TRAIL-induced apoptosis of HL60 leukemia cells: two distinct phenotypes of acquired TRAIL resistance that are accompanied with resistance to TNF alpha but not to idarubicin and cytarabine2009 | Publication without faculty affiliation
- Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: Results of AML-BFM 982006 | Second Faculty of Medicine
- Monitoring of Cardiotoxicity during Induction Chemotherapy in Acute Leukemia with Biochemical Markers2005 | First Faculty of Medicine
- Anthracycline resistance mediated by reductive metabolism in cancer cells: The role of aldo-keto reductase 1C32014 | Faculty of Pharmacy in Hradec Králové
- The Use Biochemical Markers in Cardiotoxicity Monitoring in Patients Treated for Leukemia2005 | First Faculty of Medicine
- Randomised Introduction of 2-CDA as Intensification during Consolidation for Children with High-risk AML - Results from Study AML-BFM 20042015 | Second Faculty of Medicine
- Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy2015 | Second Faculty of Medicine
- Ibrutinib plus CIT for R/R mature B-NHL in children (SPARKLE trial): initial safety, pharmacokinetics, and efficacy2020 | Second Faculty of Medicine
- Low Molecular Weight Heparins for Thromboprophylaxis during Induction Chemotherapy in Patients with Multiple Myeloma2011 | Publication without faculty affiliation
- Ibrutinib plus RICE/RVICI for R/R mature B-NHL in children/young adults: SPARKLE trial2023 | Second Faculty of Medicine
- Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial2023 | Publication without faculty affiliation